Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Filgrastim |
Synonyms | |
Therapy Description |
Neupogen (filgrastim) is a recombinant analog of granulocyte colony-stimulating factor (G-CSF) isoform B, which binds and activates G-CSF receptors modulating neutrophilic granulocyte progenitor activity, production, and differentiation (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Filgrastim | Neupogen | G-CSF | Neupogen (filgrastim) is a recombinant analog of granulocyte colony-stimulating factor (G-CSF) isoform B, which binds and activates G-CSF receptors modulating neutrophilic granulocyte progenitor activity, production, and differentiation (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
No data available in table |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01526096 | Phase I | Basiliximab Filgrastim Plerixafor Melphalan | Stem Cell Transplantation for Patients With Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT01783535 | Phase II | Cyclophosphamide Carboplatin + Doxorubicin + Vincristine Sulfate Pegfilgrastim Topotecan + Vincristine Sulfate Carboplatin + Etoposide + Vincristine Sulfate Filgrastim Carboplatin + Topotecan Carboplatin + Vincristine Sulfate | Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma | Active, not recruiting | USA | 0 |
NCT01857934 | Phase II | Doxorubicin Sargramostim Aldesleukin Vincristine Sulfate Filgrastim Tretinoin Levetiracetam Cisplatin + Etoposide Hu14.18K322A Busulfan + Melphalan Cyclophosphamide + Topotecan | Therapy for Children With Advanced Stage Neuroblastoma | Active, not recruiting | USA | 0 |
NCT02337985 | Phase I | Rituximab Cyclophosphamide + Doxorubicin + Etoposide + Vincristine Sulfate Filgrastim Prednisone | Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT02356159 | Phase Ib/II | Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate Cyclophosphamide + Fludarabine Rituximab | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | Active, not recruiting | USA | 0 |
NCT02427620 | Phase II | Cyclophosphamide + Doxorubicin + Vincristine Sulfate Filgrastim Dexamethasone Cytarabine + Methotrexate Leucovorin | A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT02790515 | Phase II | Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim | Provision of TCRgammadelta T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | Active, not recruiting | USA | 0 |
NCT03147612 | Phase II | Pegfilgrastim Blinatumomab Vincristine Sulfate Rituximab Filgrastim Ponatinib Cyclophosphamide Methotrexate Cytarabine | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients with Philadelphia Chromosome-Positive And/or BCR-ABL Positive Acute Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |
NCT03164057 | Phase II | Etoposide Filgrastim Dexrazoxane Daunorubicin Idarubicin Fludarabine Asparaginase Cytarabine Sorafenib Mitoxantrone Decitabine Azacitidine | A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03246529 | Phase III | Filgrastim BKT140 + Filgrastim | A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM (GENESIS) | Active, not recruiting | USA | ITA | HUN | ESP | DEU | 0 |
NCT03247088 | Phase Ib/II | Busulfan + Fludarabine + Sorafenib Cyclophosphamide Tacrolimus Filgrastim | Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT03907488 | Phase III | Pegfilgrastim Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Filgrastim Dacarbazine + Doxorubicin + Nivolumab + Vinblastine | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | Active, not recruiting | USA | CAN | 1 |
NCT00303849 | Phase Ib/II | Filgrastim Etoposide + Melphalan Carboplatin Pegfilgrastim | Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma | Completed | USA | 0 |
NCT00513474 | Phase I | Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide | Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant | Completed | USA | 0 |
NCT00520130 | Phase Ib/II | Cytarabine + Fludarabine Alemtuzumab + Cyclosporine Cyclophosphamide + Doxorubicin + Etoposide + Fludarabine + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Fludarabine + Prednisone + Vincristine Sulfate Methotrexate + Sirolimus + Tacrolimus Filgrastim | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | Completed | USA | 0 |
NCT00857389 | Phase II | Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate | Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | Completed | USA | 0 |
NCT01256398 | Phase II | Dexamethasone Dasatinib Tacrolimus Cyclophosphamide + Fludarabine Filgrastim Mercaptopurine + Methotrexate + Vincristine Sulfate Melphalan Cytarabine + Daunorubicin + Etoposide Pegfilgrastim Alemtuzumab Leucovorin | Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT01319981 | Phase II | Pegfilgrastim Imatinib Filgrastim Rituximab Doxorubicin Dexamethasone Vincristine Sulfate Cyclophosphamide | Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT01467115 | Phase II | Leucovorin Cisplatin + Docetaxel + Fluorouracil Filgrastim Cetuximab | INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER | Completed | USA | 0 |
NCT01505569 | Phase I | Filgrastim Busulfan + Melphalan Etoposide + Ifosfamide Thiotepa Carboplatin | Auto Transplant for High Risk or Relapsed Solid or CNS Tumors | Completed | USA | 0 |
NCT01526603 | Phase I | Melphalan Etoposide Filgrastim Tretinoin Carboplatin | High Dose Chemotherapy and Autologous Transplant for Neuroblastoma | Completed | USA | 0 |
NCT01547806 | Phase II | Filgrastim Plerixafor | Collection of Transplant Stem Cells for Plasma Cell Myeloma | Completed | USA | 0 |
NCT01701986 | Phase Ib/II | Tacrolimus Rituximab Filgrastim Mycophenolate mofetil anti-thymocyte globulin Busulfan + Clofarabine + Gemcitabine | Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas | Completed | USA | 0 |
NCT01707004 | Phase I | Cyclophosphamide Decitabine Filgrastim Fludarabine Busulfan | Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Completed | USA | 0 |
NCT01729091 | Phase Ib/II | Dexamethasone Elotuzumab Filgrastim Melphalan Lenalidomide | Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma | Completed | USA | 0 |
NCT01823198 | Phase Ib/II | Methotrexate anti-thymocyte globulin + Busulfan + Fludarabine Tacrolimus Filgrastim | Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies | Completed | USA | 0 |
NCT01858883 | Phase I | Nab-paclitaxel Filgrastim Itacitinib Gemcitabine | Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT02098109 | Phase II | Plerixafor Filgrastim | Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT02104427 | Phase II | Burixafor Filgrastim | PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | Completed | USA | 0 |
NCT02130869 | Phase I | Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | Completed | USA | 0 |
NCT02421939 | Phase III | Cytarabine Cytarabine + Fludarabine + Idarubicin Cytarabine + Etoposide + Mitoxantrone Azacitidine Gilteritinib Filgrastim | A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | Completed | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BEL | 3 |
NCT02423915 | Phase Ib/II | Filgrastim Rituximab Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus | Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | Completed | USA | 0 |
NCT02756572 | Phase I | Sirolimus Mycophenolate mofetil Cyclosporine Cytarabine Melphalan Cladribine Filgrastim mitoxantrone hydrochloride Fludarabine | Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia | Completed | USA | 0 |
NCT03197935 | Phase III | Pegfilgrastim Doxorubicin Atezolizumab Filgrastim Nab-paclitaxel Cyclophosphamide | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031) | Completed | USA | POL | ITA | GBR | ESP | DEU | CAN | BRA | BEL | AUS | 3 |
NCT03263936 | Phase I | Vorinostat Decitabine Cytarabine Fludarabine Filgrastim | Epigenetic Reprogramming in Relapse/Refractory AML | Completed | USA | CAN | AUS | 0 |
NCT04023669 | Phase I | Filgrastim Pegfilgrastim Cyclophosphamide + Prexasertib Gemcitabine + Prexasertib | Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors | Completed | USA | 0 |
NCT00074490 | Phase II | Cyclophosphamide Cyclosporine Rituximab Doxorubicin Etoposide Filgrastim Vincristine Sulfate Fludarabine | Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers | Terminated | USA | 0 |
NCT01177683 | Phase Ib/II | Bendamustine + Bortezomib + Pegylated liposomal doxorubicin Filgrastim | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma | Terminated | USA | 0 |
NCT01685411 | Phase 0 | Busulfan + Cyclophosphamide Filgrastim Allopurinol Mycophenolate mofetil anti-thymocyte globulin Tacrolimus Levetiracetam | Busulfan and Cyclophosphamide Followed By ALLO BMT | Terminated | USA | 0 |
NCT02412475 | Phase I | Cytarabine Sorafenib Vorinostat Filgrastim Daunorubicin Fludarabine Decitabine | Epigenetic Reprogramming in Relapse AML | Terminated | USA | 0 |
NCT02774291 | Phase I | Aldesleukin Cyclophosphamide + Fludarabine Filgrastim | Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1 | Terminated | USA | 0 |
NCT03860844 | Phase II | Idarubicin Cyclophosphamide Isatuximab Doxorubicin Etoposide Daunoxome Cytarabine Methotrexate Daunorubicin Fludarabine Dexamethasone Mitoxantrone Filgrastim Vincristine Sulfate Pegaspargase | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | Terminated | USA | SWE | NOR | NLD | ITA | HUN | GRC | FRA | DNK | DEU | BRA | ARG | 4 |
NCT00983398 | Phase Ib/II | Pegfilgrastim Filgrastim Carboplatin + Melphalan | Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors | Unknown status | USA | 0 |
NCT02343666 | Phase I | Filgrastim Carmustine Plerixafor O6-benzylguanine | HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection | Withdrawn | USA | 0 |
NCT03579927 | Phase Ib/II | Filgrastim iC9-CAR.19-IL15-Transduced CB-NK Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | Withdrawn | USA | 0 |
CKB CORE allows for only a limited number of monthly page views for un-registered users. However, registration is free and allows for unlimited browsing of the CKB CORE content.
You have reached the monthly page view limit. For continued free access to CKB CORE, please register below: